Abstract

REVIEW ON LIPID NANOPARTICLES OF TAZAROTENE FOR TREATMENT OF PSORIASIS

aizan Qureshi, *Mrs. Sarita Yeole, Dr. Preeti Kulkarni, Ms. Amrita Bhoyar, Ms. Shashikala Bulgunde, Mrs. Abhilasha Dubey, Mrs. Akshara Indulkar, Mrs. Disha Devkar, Mr. Prasad Shirole

ABSTRACT

Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by accelerated keratinocyte proliferation and dysregulated immune responses, leading to visible skin lesions such as erythematous plaques and scales. Normally, skin cells mature and shed over a month; however, in psoriasis this process occurs within 3–4 days, causing cellular accumulation on the skin surface. Globally, psoriasis affects approximately 2–3% of the population, with notable gender and age variations, including a higher prevalence among men in India. The disease presents in multiple forms, including plaque, inverse, guttate, pustular, and erythrodermic psoriasis, each differing in severity, distribution, and clinical features. Plaque psoriasis is the most common type, accounting for 80–90% of cases. Psoriasis is associated with significant complications such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, psychological disorders, and increased cancer risk. Clinical manifestations commonly include thick scaly plaques,dry and cracked skin, and nail abnormalities. Management involves topical agents such as corticosteroids, vitamin D analogs, retinoid, and other anti-inflammatory therapies. Pathologically, psoriasis is a T-cell–mediated disease involving keratinocytes, dendritic cells, neutrophils, and cytokines, particularly those associated with Th1 and Th17 pathways. Cytokines such as IL-17A and IL-17F play a crucial role in sustaining inflammation and lesion development. Understanding the immunopathogenesis of psoriasis is essential for developing targeted therapies and improving disease management and patient outcomes.

Keywords: Psoriasis, Autoimmune disease, Keratinocyte hyper proliferation, T-cell mediated inflammation, Plaque psoriasis, Th17 pathway, Interleukin-17, Psoriatic arthritis, Chronic inflammatory skin disease, Immunopathogenesis.